Jessica Fye
Stock Analyst at JP Morgan
(3.91)
# 530
Out of 4,829 analysts
182
Total ratings
52.17%
Success rate
7.92%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $512 → $515 | $424.99 | +21.18% | 8 | May 6, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Overweight | $10 → $13 | $9.97 | +30.39% | 6 | May 6, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $200 → $245 | $151.46 | +61.76% | 11 | May 2, 2025 | |
| UTHR United Therapeutics | Maintains: Overweight | $355 → $350 | $301.42 | +16.12% | 16 | May 1, 2025 | |
| INCY Incyte | Maintains: Neutral | $70 → $68 | $58.98 | +15.29% | 6 | Apr 21, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $55 → $58 | $65.87 | -11.95% | 12 | Apr 21, 2025 | |
| ONC BeiGene | Maintains: Overweight | $311 → $317 | $231.99 | +36.64% | 1 | Apr 21, 2025 | |
| IMCR Immunocore Holdings | Maintains: Overweight | $54 → $50 | $28.40 | +76.06% | 5 | Apr 14, 2025 | |
| NVCR NovoCure | Maintains: Neutral | $29 → $28 | $17.38 | +61.10% | 4 | Apr 10, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Neutral | $47 → $45 | $32.30 | +39.34% | 4 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $280 → $328 | $251.15 | +30.60% | 5 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $40 → $33 | $24.25 | +36.08% | 12 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $209 | $97.78 | +113.75% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $92 | $65.08 | +41.36% | 7 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $24 | $14.37 | +67.01% | 5 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $124 → $122 | $92.87 | +31.37% | 10 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $109 | $58.86 | +85.19% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $32 → $26 | $30.13 | -13.71% | 6 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $11.11 | +170.03% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $54 | $30.68 | +76.01% | 5 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $39 | $44.27 | -11.90% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $13 | $9.36 | +38.89% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $0.59 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $5.65 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $0.80 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $10.38 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $76 | $31.78 | +139.14% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.60 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.25 | +1,660.00% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $0.70 | +898.57% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $27 | $29.34 | -7.98% | 5 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.32 | - | 4 | Mar 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $5.98 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.27 | - | 1 | Feb 8, 2018 |
Vertex Pharmaceuticals
May 6, 2025
Maintains: Overweight
Price Target: $512 → $515
Current: $424.99
Upside: +21.18%
BioCryst Pharmaceuticals
May 6, 2025
Maintains: Overweight
Price Target: $10 → $13
Current: $9.97
Upside: +30.39%
Ascendis Pharma
May 2, 2025
Maintains: Overweight
Price Target: $200 → $245
Current: $151.46
Upside: +61.76%
United Therapeutics
May 1, 2025
Maintains: Overweight
Price Target: $355 → $350
Current: $301.42
Upside: +16.12%
Incyte
Apr 21, 2025
Maintains: Neutral
Price Target: $70 → $68
Current: $58.98
Upside: +15.29%
Halozyme Therapeutics
Apr 21, 2025
Maintains: Neutral
Price Target: $55 → $58
Current: $65.87
Upside: -11.95%
BeiGene
Apr 21, 2025
Maintains: Overweight
Price Target: $311 → $317
Current: $231.99
Upside: +36.64%
Immunocore Holdings
Apr 14, 2025
Maintains: Overweight
Price Target: $54 → $50
Current: $28.40
Upside: +76.06%
NovoCure
Apr 10, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $17.38
Upside: +61.10%
Ionis Pharmaceuticals
Mar 24, 2025
Maintains: Neutral
Price Target: $47 → $45
Current: $32.30
Upside: +39.34%
Mar 24, 2025
Upgrades: Overweight
Price Target: $280 → $328
Current: $251.15
Upside: +30.60%
Mar 21, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $24.25
Upside: +36.08%
Feb 26, 2025
Maintains: Overweight
Price Target: $200 → $209
Current: $97.78
Upside: +113.75%
Feb 7, 2025
Maintains: Overweight
Price Target: $83 → $92
Current: $65.08
Upside: +41.36%
Jan 7, 2025
Maintains: Overweight
Price Target: $28 → $24
Current: $14.37
Upside: +67.01%
Nov 26, 2024
Maintains: Neutral
Price Target: $124 → $122
Current: $92.87
Upside: +31.37%
Oct 30, 2024
Maintains: Overweight
Price Target: $110 → $109
Current: $58.86
Upside: +85.19%
Oct 25, 2024
Maintains: Neutral
Price Target: $32 → $26
Current: $30.13
Upside: -13.71%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $11.11
Upside: +170.03%
Jul 9, 2024
Maintains: Overweight
Price Target: $47 → $54
Current: $30.68
Upside: +76.01%
Jun 18, 2024
Maintains: Overweight
Price Target: $31 → $39
Current: $44.27
Upside: -11.90%
Mar 26, 2024
Maintains: Neutral
Price Target: $6 → $13
Current: $9.36
Upside: +38.89%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $0.59
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $5.65
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $0.80
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $10.38
Upside: -
Apr 19, 2023
Maintains: Overweight
Price Target: $65 → $76
Current: $31.78
Upside: +139.14%
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.60
Upside: -
Apr 19, 2021
Initiates: Overweight
Price Target: $22
Current: $1.25
Upside: +1,660.00%
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $0.70
Upside: +898.57%
May 12, 2020
Maintains: Overweight
Price Target: $32 → $27
Current: $29.34
Upside: -7.98%
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $0.32
Upside: -
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $5.98
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $5.27
Upside: -